MAEA: Key Enzyme in Glycosaminoglycan and Cell Surface Carbohydrate Regulation

Target Name: MAEA

NCBI ID: G10296

MAEA

MAEA: Key Enzyme in Glycosaminoglycan and Cell Surface Carbohydrate Regulation

MAEA (Mannosylated Alpha-glucosaminidase) is a protein that is expressed in various tissues throughout the body, including the liver, spleen, and muscle. It is a key enzyme in the glycosaminoglycan (GAG) pathway, which is a complex process that involves the production of glycosaminoglycans from dietary carbohydrates. This pathway is important for the maintenance of cellular structure and function, and is also involved in the regulation of inflammation and other cellular processes.

One of the unique features of MAEA is its ability to catalyze the transfer of a mannose unit from the substrate to the alpha-glucosaminidase active site. This transfer is critical for the efficient production of GAGs, and is a critical step in the GAG pathway. MAEA has been shown to play a key role in the regulation of GAG levels, and is involved in the regulation of various cellular processes, including inflammation, fibrosis, and autophagy.

In addition to its role in GAG regulation, MAEA has also been shown to play a key role in the regulation of cell surface carbohydrates (CSCs). CSCs are a type of cell that have a unique carbohydrate structure, and are involved in various cellular processes, including cancer progression and immune evasion. MAEA has been shown to play a key role in the regulation of CSC properties, and is involved in the production of CSCs with specific carbohydrate structures.

Furthermore, MAEA has also been shown to play a key role in the regulation of inflammation and other cellular processes. It has been shown to be involved in the regulation of various cellular signaling pathways, including TGF-beta signaling, NF-kappa-B signaling, and the regulation of cytokine production.

In conclusion, MAEA is a protein that has important role in various cellular processes, including GAG regulation, CSC regulation, and inflammation. Its unique ability to catalyze the transfer of mannose unit from the substrate to the alpha-glucosaminidase active site makes it an attractive drug target, and its role in the regulation of GAG, CSC and inflammation makes it a potential biomarker. Further studies are needed to fully understand the role of MAEA in these processes and its potential as a drug or biomarker.

Protein Name: Macrophage Erythroblast Attacher, E3 Ubiquitin Ligase

Functions: Core component of the CTLH E3 ubiquitin-protein ligase complex that selectively accepts ubiquitin from UBE2H and mediates ubiquitination and subsequent proteasomal degradation of the transcription factor HBP1. MAEA and RMND5A are both required for catalytic activity of the CTLH E3 ubiquitin-protein ligase complex (PubMed:29911972). MAEA is required for normal cell proliferation (PubMed:29911972). The CTLH E3 ubiquitin-protein ligase complex is not required for the degradation of enzymes involved in gluconeogenesis, such as FBP1 (PubMed:29911972). Plays a role in erythroblast enucleation during erythrocyte maturation and in the development of mature macrophages (By similarity). Mediates the attachment of erythroid cell to mature macrophages; this MAEA-mediated contact inhibits erythroid cell apoptosis (PubMed:9763581). Participates in erythroblastic island formation, which is the functional unit of definitive erythropoiesis. Associates with F-actin to regulate actin distribution in erythroblasts and macrophages (By similarity). May contribute to nuclear architecture and cells division events (Probable)

The "MAEA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAEA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets